Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

  title={Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.},
  author={Andrew Menzies-Gow and Jonathan Corren and Arnaud Bourdin and Geoffrey Lowell Chupp and Elliot Israel and Michael E. Wechsler and Christopher E. Brightling and Janet M. Griffiths and {\AA}sa Hellqvist and Karin Bowen and Primal P. Kaur and Gun Almqvist and Sandhia Ponnarambil and Gene L. Colice},
  journal={The New England journal of medicine},
  volume={384 19},
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patients with severe, uncontrolled asthma require further assessment. METHODS We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Patients (12 to 80 years of age) were randomly assigned to receive tezepelumab (210 mg) or placebo subcutaneously… 
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Treatment with tezepelumab resulted in a nominally significantly greater reduction from baseline to the end of treatment in airway submucosal eosinophils versus placebo, with the difference seen across all baseline biomarker subgroups.
The choice of biologics in patients with severe chronic rhinosinusitis with nasal polyps.
All biologics improved the co-primary end point of nasal airway blockage and also reduced the need for rescue medical/surgical polypectomy in patients who are at increased risk for disease recurrence.
Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
  • Shih-Lung Cheng
  • Medicine
  • 2021
The aim of the study is to review the immunopathology and treatment efficacy for severe asthma and focused on new biological agents with benralizumab (anti-IL-5) and tezepelumab(anti-TSLP).
Biologics in the Treatment of Severe Uncontrolled Asthma in Children
  • N. Syabbalo
  • Journal of Thoracic Disease and Cardiothoracic Surgery
  • 2021
Asthma is the most common chronic disease in children, currently affecting about 7 million children. Severe uncontrolled asthma is rare in children with a prevalence of about 2.1% to 5%, but inflicts
Anti-Interleukin Biologics for the treatment of the Atopic March Diseases
The atopic march refers to the natural history of allergic disorders as they develop from infancy to childhood. Classically, the atopic march begins with atopic dermatitis (AD), followed by food
Novel therapeutic approaches targeting endotypes of severe airway disease
This review provides the clinician with an overview of the prevalence and clinical impact of severe chronic upper and lower airways disease and suggests a novel therapeutic approach with biological agents with possible biomarkers.
Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
The fully human anti-TSLP monoclonal antibody tezepelumab has been evaluated in very promising randomized clinical trials and is likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma.
Biological therapy for severe asthma
The aim of this article was to review the biologic therapies currently available for the treatment of severe asthma, in order to help physicians to choose the most suitable biologic agent for their asthmatic patients.
How I do it. Work-up of severe asthma.
After assessment of treatment adherence and exclusion of relevant comorbidities, the patient was found to have severe asthma with ICS-resistant type-2 airway inflammation.
Precision medicine in bronchiectasis
Bronchiectasis, due to its highly heterogenous nature, requires an individualised approach to therapy. Patients experience symptoms and exacerbations driven by a combination of impaired mucociliary